Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03737643 · ClinicalTrials.gov registry record · Phase 3
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
A Phase 3 study of Advanced Ovarian Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,407
- Enrollment target
- 20
- Study locations
NCT03737643: Active Phase 3 study of Advanced Ovarian Cancer, sponsored by AstraZeneca.
NCT03737643 is a Phase 3 study of Advanced Ovarian Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,407 participants, above the 241-participant average among 3 other Advanced Ovarian Cancer trials with a reported enrollment target (484% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03737643, a Phase 3 study of Advanced Ovarian Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,407 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Primary Outcome
To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison o
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Olaparib
- DRUG Durvalumab
- DRUG Placebo olaparib
- DRUG Durvalumab placebo
Study Locations (20)
California
- Research Site - Foothill Ranch
- Research Site - Los Angeles
- Research Site - Orange
- Research Site - San Francisco
New York
- Research Site - Albany
- Research Site - New York
- Research Site - Uniondale
Ohio
- Research Site - Cleveland
- Research Site - Dayton
- Research Site - Hilliard
New Jersey
- Research Site - Middletown
- Research Site - Montvale
Florida
- Research Site - Tampa
Georgia
- Research Site - Augusta
Illinois
- Research Site - Hinsdale
Indiana
- Research Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,407 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 3 |
What the registry record for NCT03737643 still lists
NCT03737643 is an interventional study that assigns participants to a tested intervention. Its 1,407 participants enrollment target places it among the larger protocols in the corpus, above the 241-participant average among 3 other Advanced Ovarian Cancer trials with a reported enrollment target (484% higher).
The record links to 1 condition, with Advanced Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03737643 names 20 study sites across 12 states, led by California, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT03737643 about?
NCT03737643 is a clinical study titled "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients". This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients w...
What is the current status of trial NCT03737643?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,407 participants. The study started on 2019-01-04. Estimated completion is 2028-03-30.
What conditions does trial NCT03737643 study?
This clinical trial studies the following conditions: Advanced Ovarian Cancer.
What interventions are being tested in trial NCT03737643?
The interventions under investigation include: Bevacizumab (DRUG), Olaparib (DRUG), Durvalumab (DRUG), Placebo olaparib (DRUG), Durvalumab placebo (DRUG).
Who is sponsoring clinical trial NCT03737643?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03737643 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
ACTIVE NOT RECRUITING · Phase 3
-
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
RECRUITING · Phase 2
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI